Published:
Last updated:
N/A
ID
NL-OMON32962
Source
ToetsingOnline
Brief title
LY2562175 MAD/DDI/FE study
Condition
- Lipid metabolism disorders
Synonym
lipids, metabolism
Research involving
Human
Sponsors and support
Primary sponsor
:
Chorus, Lilly Research Laboratories
Source(s) of monetary or material Support
:
Chorus;Lilly Research Laboratories USA
Intervention
Keyword
:
Dyslipidemie, LY2562175
Outcome measures
Primary outcome
N/A
Secondary outcome
N/A
Background summary
N/A
Study objective
N/A
Study design
N/A
Intervention
N/A
Study burden and risks
N/A
Public
Chorus, Lilly Research Laboratories
450 S. Meridian, Dock 520, DC6034
IN46225 Indianapolis
USA
450 S. Meridian, Dock 520, DC6034
IN46225 Indianapolis
USA
Scientific
Chorus, Lilly Research Laboratories
450 S. Meridian, Dock 520, DC6034
IN46225 Indianapolis
USA
450 S. Meridian, Dock 520, DC6034
IN46225 Indianapolis
USA
Listed location countries
Netherlands
Age
Adults (18-64 years)
Elderly (65 years and older)
Inclusion criteria
Healthy men or women of non child bearing potential
18 - 65 year inclusive
BMI 18-30 kg/m2
Exclusion criteria
Zie vraag 5b
Design
Study type
:
Interventional
Intervention model
:
Parallel
Allocation
:
Randomized controlled trial
Masking
:
Double blinded (masking used)
Control
:
Placebo
Primary purpose
:
Treatment
Recruitment
NL
Recruitment status
:
Recruitment stopped
Start date (anticipated)
:
Enrollment
:
57
Type
:
Actual
Approved WMO
Date
:
Application type
:
First submission
Review commission
:
BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO
Date
:
Application type
:
First submission
Review commission
:
BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
EudraCT | EUCTR2009-013167-19-NL |
CCMO | NL28974.056.09 |